Craft
Incyte

Incyte

Revenue

$3 B

FY, 2021

Market Capitalization

$15.1 B

2022-09-20

Incyte Summary

Company summary

Overview
Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The Company develops Jakafi (ruxolitinib), a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera when there has been an inadequate response to or intolerance of hydroxyurea.
Type
Public
Founded
1991
HQ
Wilmington, DE, US | view all locations
Website
http://www.incyte.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Hervé Hoppenot

    Hervé Hoppenot, Chairman, President and Chief Executive Officer

    • Michael Booth D.phil, Division VP, Investor Relations & Corporate Responsibility Phone: 302.498.5914

      • Jonathan E Dickinson

        Jonathan E Dickinson, Executive Vice President, General Manager, Europe

        • Lauren Ayala, Senior Director, Investor Relations & Corporate Responsibility

          LocationsView all

          12 locations detected

          • Wilmington, DE HQ

            United States

            1801 Augustine Cut Off

          • Wien, Wien

            Austria

            DC Tower 1, Donau-City-Straße 7

          • Pointe-Claire, QC

            Canada

            6500 Trans-Canada Hwy # 400

          • Frederiksberg

            Denmark

            Suomisvej 4

          • Boulogne-Billancourt, IDF

            France

            35 Ter Av. André Morizet

          • München, BY

            Germany

            Perchtinger Str. 8

          and 6 others

          Incyte Financials

          Summary financials

          Revenue (Q2, 2022)
          $911.4M
          Gross profit (Q2, 2022)
          $860.8M
          Net income (Q2, 2022)
          $161.4M
          Cash (Q2, 2022)
          $2.4B
          EBIT (Q2, 2022)
          $254.4M
          Enterprise value
          $12.7B

          Footer menu